Venetoclax, azacitidine, and chidamide in combination with cytarabine, aclarubicin, and G-CSF as induction chemotherapy for myelodysplasia-related acute myeloid leukemia
A new drug combination for blood cancers outperformed standard chemotherapy in early results, though larger studies are needed to confirm benefits.
This retrospective study (n=30+30) shows that the novel CACAG-VEN regimen (venetoclax + azacitidine + chidamide + cytarabine + aclarubicin + G-CSF) achieves superior CR and survival compared to standard 3+7 chemotherapy in myelodysplasia-related AML. Results are promising but limited by small sample size, retrospective design, and single-center Chinese PLA hospital setting.
What the study was
- Study design
- Retrospective comparative cohort study
- Population
- AML-MR (myelodysplasia-related AML) patients age 14-75
- Sample size
- 60
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Clin Exp Med
Why it surfaced
Promising CR rates for a notoriously difficult-to-treat AML subtype. However n=30 per arm, retrospective, single center — requires prospective validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.